AKARI THERAPEUTICS, PLC

• ⚠

  Material uncertainty over going concern

  Management has concluded that these outcomes represent material uncertainties that cast significant doubt regarding the Group's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.

1. AKARI THERAPEUTICS, PLC 2015-09-17 → present
2. CELSUS THERAPEUTICS PLC 2013-06-25 → 2015-09-17
3. MORRIA BIOPHARMACEUTICALS PLC 2005-02-15 → 2013-06-25
4. FRESHNAME NO.333 LIMITED 2004-10-07 → 2005-01-19

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

HaysMac LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“Management has concluded that these outcomes represent material uncertainties that cast significant doubt regarding the Group's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.”

Group structure

1. AKARI THERAPEUTICS, PLC · parent
   1. Volution Immuno Pharmaceuticals SA 100% · Switzerland · Development of pharmaceutical drugs
   2. Celsus Therapeutics Inc. 100% · United States · Dormant
   3. Morria Biopharma Ltd. 100% · Israel · Dormant
   4. Akari Malta Limited 100% · Malta · Regulatory compliance
   5. Peak Bio Incorporated 100% · United States · Development of pharmaceutical drugs
   6. Peak Bio Corporation Limited 100% · South Korea · Development of pharmaceutical drugs
   7. Ignyte Korea Corporation Limited 100% · South Korea · Dormant
   8. Peak Bio California Incorporated 100% · United States · Development of pharmaceutical drugs

Significant events

• “On 2 March 2025, the Company entered into a securities purchase agreement (the "March 2025 Purchase Agreement") with certain investors, including the Company's Chairman, Dr. Hoyoung Huh, director, President and Chief Executive Officer, Dr. Samir R. Patel, and all other members of the Company's board, pursuant to which the Company agreed to sell and issue in a private placement (the "March 2025 Offering") an aggregate of 6,637,626 unregistered ADSs...”
• “On 3 March 2025, the Company signed a Settlement Agreement and Mutual Release with a former consultant to settle the demand letter claims received in December 2024.”
• “On 13 March 2025, the Company entered into an Executive Offer of Employment Agreement... with Mr. Abizer Gaslightwala pursuant to which Mr. Gaslightwala will serve as the President and Chief Executive Officer of the Company, effective on 21 April 2025.”
• “On 17 March 2025, Dr. Huh's January 2024 Note was amended to extend the maturity date to 31 December 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

18

last 12 months

Capital events

10

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -32.4%

  £2,850,259 → £1,926,612

• Net assets

  +2,234.8%

  £732,394 → £17,100,074

• Employees

  -44.4%

  18 → 10

• Operating profit

  -11.3%

  -£15,152,706 → -£16,870,274

• Profit before tax

  -55.2%

  -£9,954,781 → -£15,451,446

• Wages

  -58.5%

  £3,158,636 → £1,312,083

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers